there are many factors responsible for residual risks of vascular events, atherogenic dyslipidemia is the most important factor.
有许多因素影响血管剩留风险的存在,其中最为重要的是致动脉粥样硬化性血脂异常。
the benefit of fenofibrate was only seen in the pre-specified group of diabetic patients with atherogenic dyslipidemia and not in the total study population.
非诺贝特的疗效之前只在事先分好的患动脉粥状硬化癥的糖尿病人小组相传而不是全部的研究对象人员中。
in fact, the risk associated with atherogenic dyslipidemia was comparable to that in people with previous cardiovascular disease (17.3 percent versus 18.1 percent).
实际上,伴随致动脉粥状硬化癥的风险同先前患过心血管病的风险相仿(17.3%比18.1%)。
atherogenic dyslipidemia is common and the prevalence is markedly increasing as a result of the global epidemic of type 2 diabetes, obesity and metabolic syndrome.(8)
粥状动脉硬化很常见并且越来越普遍,因为2型糖尿病,肥胖和代谢侯癥成为国际性通病。
given the magnitude of the global epidemic of type 2 diabetes - especially in developing regions - targeting atherogenic dyslipidemia is crucial.
照2型糖尿病的国际范围,尤其是发展中地区,瞄準粥状动脉硬化很重要。